Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Placebo-controlled Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Effects on Transcranial Magnetic Stimulation of Oral Administration of XEN1101 in Healthy Male Subjects

Trial Profile

A Double-blind, Placebo-controlled Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Effects on Transcranial Magnetic Stimulation of Oral Administration of XEN1101 in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Sep 2018

At a glance

  • Drugs XEN 1101 (Primary)
  • Indications Epilepsy
  • Focus Adverse reactions; Biomarker; Pharmacodynamics
  • Sponsors Xenon Pharmaceuticals
  • Most Recent Events

    • 10 Sep 2018 Status changed from active, no longer recruiting to completed, according to a Xenon Pharmaceuticals media release.
    • 29 Aug 2018 According to a Xenon Pharmaceuticals media release, lead investigator, Dr. Isabella Premoli of this XEN1101 phase 1b TMS study will be presenting the results in a podium presentation at the 13th European Congress on Epileptology held in Vienna, Austria today.
    • 29 Aug 2018 Results of this phase Ib, cross-over TMS study presented in a Xenon Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top